Kick Back: The 10 biggest stories you might have missed on Stockhead this week
Link copied to
Welcome to one of the biggest weekend of sports in Australia. AFL, NFL, Cox Plate… oh my.
But first, we already have a loser – whoever’s idea it was to “put the G in the Gabba” ahead of Saturday’s final between Richmond and Geelong in Brisbane:
— Mark Gottlieb (@MarkGottlieb) October 22, 2020
What you’re looking at there is a chunk of the MCG that was ripped up and taken by refrigerated truck to the Gabba, because Victorians just couldn’t bear to see an MCG-less Grand Final.
For the rest of Australia that lives in Reality World, here’s the important news you might have missed during the week.
Dope is dope again. If you thought the bud market bong had lost its bubble a bit, here’s a fast $1 million that says it’s back. The fastest $1 million in fact, to be reached in Australian crowdfunding history. It took all of 36 hours and 36 minutes for Montu to hit that magic mark when it kicked off its capital raise on Birchal last week.
Montu’s minimum target of $300,000 was hit in just under an hour.
So what makes Montu different? Relationships.
Montu essentially provides a matchmaking service for patients that need medicinal cannabis to doctors that will give it to them.
Studies show just about any doctor’s patient group hold 20-30 per cent that could be treated with medicinal cannabis. And currently in Australia, only around 5 per cent of GPs are prescribing medicinal cannabis…
Last week, we got some US election tips and ASX stock picks from VFS Group’s pro investor James Whelan. Among them:
“One of the easiest investment strategies with mining stocks is if you see Tolga (Kumova’s) name pop up on the registry, you probably want to own that stock,” he said.
Within seven days, those who listened to that sage advice had two options.
Locked out of Diggers and Dealers, and restricted to his home base in bayside Melbourne with nothing bu a garage gym and his new abs, Kumova told Garimpeiro he had made his “own De Grey play”, by wangling a potential 10 per cent of Raiden Resources (ASX:RDN). Raiden’s looking to add a Pilbara gold and nickel leg to its existing Balkans gold-copper exploration story.
And in the same week, Kumova liked progress at Firefly Resources (ASX: FFR) so much he upped his stake in a capital raise to 6.55 per cent. That makes him a substantial holder in the company that’s hoping to hit gold in untested historical high-grade mines in WA’s Yalgoo goldfield.
Make that, “stories” with BNPL in them, starting with an Afterpay (ASX: APT) announcement of an announcement to come that had excitable investors on the edge of their seats for days. When it dropped, on Tuesday, APT hit the $100 mark immediately.
And you got it, with Westpac allowing Afterpay onto its new digital banking platform. That gives Afterpay users access to Westpac transaction and savings accounts and other cashflow management tools.
And Zip wasn’t to be outdone. On the same day it announced Zip users could “Tap and Zip” with their Visa cards. That sounds like a big green tick for Zip, but some analysts weren’t so sure.
Distribution is obviously excellent, but will it come at the cost of cannibalising the higher margins Zip’s been collecting on its own platform?
Whatever. The froth around all this type of tech money being thrown around is now rising high enough that biz journos are asking Afterpay co-founder Anthony Eisen if he could ever see the tech sector eclipsing mining to take the No 2 spot on the local bourse.
There’s an inquiry into Crown Casino going on and it involves a bloke by the name of Aspinall. Cue any excuse for TSB to reminisce about the glory days of taking shameless advantage of inbred interns, Bond-level croupiers and doormen with the class to accept your left shoe as collateral.
They don’t call it the Good Old Days for nothing, you know.
The final US Presidential Debate has been run and … maybe halved. But Joe Biden is still real clear in the polls that matter, so we’re sticking with the theme of what happens to gold once Trump is shown the door?
Here’s Guy le Page, former geologist and experienced stockbroker, to tell you:
“There are only a few possible outcomes — there’s either going to be a lift in gold and a fall in the Australian dollar, there’s going to be exploration success, or a correction is coming up. I would suggest the most likely outcome is a rise in the gold price.”
There’s more here on the outlook for EV metals demand, as well as this week’s movers, shakers and hot stocks to watch.
But if you’re the kind of reader that needs 105 ASX stocks with exposure to lithium, cobalt, graphite, nickel, and vanadium on a table, Reuben Adams is there for you:
Scroll or swipe to reveal table. Click headings to sort. Best viewed on a laptop:
Nickel investor sentiment in particular is currently flying — 11 of the top 20 battery metals stocks (55 per cent) over the past month have nickel exposure.
Among the standouts is Pure Minerals (ASX:PM1), which inked an offtake-potential project funding deal with the world’s biggest electric vehicle battery maker, LG Chem.
It’s not all about Tesla, you know.
How’s your hafnium play working out for you?
Probably pretty good, especially if you have the first clue what hafnium actually is. Because you’d also be aware that it’s one of those critical minerals China’s trying to shore up by tightening its control on exports.
Alarming: China accounts for 63 per cent of global rare earths production.
Interesting: Australia has 9 of the other 37 per cent.
But where is it all? Here, silly, in the Australian Critical Minerals Prospectus 2020 released on Wednesday. It lists 200 greenfield mining projects for 24 critical minerals found in Australia, clearly labelled for international investors to get a handle on and piece of.
Note: What doesn’t appear here – two million tonnes cabbage, of which is suddenly in massive demand in South Korea. Extreme weather has wiped out the crops of their favourite vegetable to pickle for kimchi.
2020 was never going to be the year where we could stop using the “still no cure for cancer” meme.
But it has shown itself to be an exciting time in the cancer-fighting biotech space. And by that we mean “an exciting time to be investing in the sector”.
If you’d jumped on Race Oncology (ASX:RAC) 16 months ago after its positive clinical trials of chemotherapy drug Bisantrene, you’d be up more than 16-fold right now.
No surprise then that there’s been a bit of a rush on to be – or find – the next Race Oncology. And the deals are eye-watering, such as the cool $US21 billion for Immunomedics (NASDAQ:IMMU), or the $US4.2 billion Merck & Co committed to Seattle Genetics (NASDAQ:SGEN).
Here are the cancer-fighting biotechs closer to home that a) you can actually afford, and b) are showing signs of riding the cancer-fighting wave.
Making money off stocks is … hard. For starters, it’s arguably easier if you have a ton of money to lose. More than $2.5 million, in fact, or earning at least $250,000 a year. That will allow you get a Sophisticated Investor Certificate, which opens a few more doors into what you’re allowed to spend your money on.
Such as options. Options, for the uninitiated, give investors more flexible ways to construct their portfolios. It’s really, really interesting and clearly a great way to hedge against something horrifying such as the BNPL market tanking.
So here’s the essential one-minute breakdown from Sam Jacobs:
Actually, wait. Here’s the essential one-minute breakdown from Sam Jacobs.
OK, because you probably didn’t get down this far and Melbourne is unstoppable as ‘Most Ridiculous Thing’ this week, here’s our ropey list of stocks that might get a kick out of their loose association with the football grand finals this week.
Be nice. They at the very least need your help.
Have a great weekend, may the best team/horse win. And may no one blow their ankle out on that dodgy sideline at the ‘Gabba.